260 related articles for article (PubMed ID: 38737333)
1. A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds.
Nazir MS; Ahmad M; Aslam S; Rafiq A; Al-Hussain SA; Zaki MEA
Drug Des Devel Ther; 2024; 18():1547-1571. PubMed ID: 38737333
[TBL] [Abstract][Full Text] [Related]
2. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
4. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study.
Rabie AM; Eltayb WA
Mol Biotechnol; 2024 Apr; 66(4):592-611. PubMed ID: 36690820
[TBL] [Abstract][Full Text] [Related]
5. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
6. Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic.
Negi M; Chawla PA; Faruk A; Chawla V
Bioorg Chem; 2020 Nov; 104():104315. PubMed ID: 33007742
[TBL] [Abstract][Full Text] [Related]
7. Multi-Targeted Molecular Docking and Drug-Likeness Evaluation of some Nitrogen Heterocyclic Compounds Targeting Proteins Involved in the Development of COVID-19.
Hui LY; Mun CS; Sing LC; Rajak H; Karunakaran R; Ravichandran V
Med Chem; 2023; 19(3):297-309. PubMed ID: 35713125
[TBL] [Abstract][Full Text] [Related]
8. Metal-Promoted Heterocyclization: A Heterosynthetic Approach to Face a Pandemic Crisis.
Rossi FV; Gentili D; Marcantoni E
Molecules; 2021 Apr; 26(9):. PubMed ID: 33947170
[TBL] [Abstract][Full Text] [Related]
9. SAR based Review on Diverse Heterocyclic Compounds with Various Potential Molecular Targets in the Fight against COVID-19: A Medicinal Chemist Perspective.
Madan A; Garg M; Satija G; Sharma B; Shaquiquzzaman M; Akhter M; Iqubal A; Khan MA; Parvez S; Das A; Sheikh KA; Alam MM
Curr Top Med Chem; 2023; 23(14):1319-1339. PubMed ID: 36703601
[TBL] [Abstract][Full Text] [Related]
10. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
Awadasseid A; Wu Y; Tanaka Y; Zhang W
Biomed Pharmacother; 2021 May; 137():111330. PubMed ID: 33550043
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in N-Heterocycles for COVID-19 Treatment - A Mini Review.
Dinodia M
Med Chem; 2023; 19(8):717-729. PubMed ID: 36852805
[TBL] [Abstract][Full Text] [Related]
12. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
Kundu S; Sarkar D
Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
[TBL] [Abstract][Full Text] [Related]
14. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
16. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Łos MJ
Drug Resist Updat; 2020 Dec; 53():100719. PubMed ID: 32717568
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.
Malik P; Jain S; Jain P; Kumawat J; Dwivedi J; Kishore D
Arch Pharm (Weinheim); 2022 May; 355(5):e2100382. PubMed ID: 35040187
[TBL] [Abstract][Full Text] [Related]
18. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
19. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges.
Wang Z; Yang L
J Med Virol; 2022 Apr; 94(4):1373-1390. PubMed ID: 34897729
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
